Ask AI

Think You Know JAK? Essential Evidence to Aid Your Clinical Implementation of JAK Inhibitors in Atopic Dermatitis, Alopecia Areata, and Vitiligo

Video
This activity is available for 1.00 CME/CE credit(s).

Released: November 17, 2026

Expiration: November 16, 2027

See Activity Collection

JAK inhibitors are efficacious and safe to use in several dermatologic conditions, including atopic dermatitis, alopecia areata, and vitiligo. Access this on-demand webcast to review the latest data and learn how to safely integrate FDA-approved JAK inhibitors in your practice by optimizing patient selection, risk assessment, shared decision-making, and monitoring to support patients’ individualized care and long-term disease control.

Think you know JAK webcast

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
1.

How many people with atopic dermatitis, alopecia areata, and/or vitiligo do you provide care for in a typical week?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

How comfortable are you prescribing JAK inhibitors for patients with AD, AA, and/or vitiligo?

4.

A patient with moderate to severe AD has recurrent flares, persistent itch, and sleep disruption despite optimized topical therapy. They prefer an oral option and ask how JAK inhibitors may fit into their treatment planning. Which counseling point is incorrect and should be revised?

5.

A patient with severe alopecia areata is starting an approved JAK inhibitor after several years of progressive disease. Which counseling point is incorrect and should be revised?

6.

A 26-yr-old with nonsegmental vitiligo asks whether topical JAK inhibitor therapy is likely to help. She has several facial and neck lesions with perifollicular pigmentation, scattered dorsal hand lesions, and a few fingertip lesions with leukotrichia. She reports some recent spread over the past 3 mo. Based on this patient, which option is the least accurate?